Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs

MLA

Yolanda Macías, et al. “Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs.” Frontiers in Pharmacology, vol. 12, Sept. 2021. EBSCOhost, https://doi.org/10.3389/fphar.2021.648262.

APA

Yolanda Macías, Jesús M. García-Menaya, Manuel Martí, Concepción Cordobés, Raquel Jurado-Escobar, José A. Cornejo-García, María J. Torres, Natalia Blanca-López, Gabriela Canto, Miguel Blanca, José J. Laguna, Joan Bartra, Ana Rosado, Javier Fernández, Elena García-Martín, & José A. G. Agúndez. (2021). Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.648262

Chicago

Yolanda Macías, Jesús M. García-Menaya, Manuel Martí, Concepción Cordobés, Raquel Jurado-Escobar, José A. Cornejo-García, María J. Torres, et al. 2021. “Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs.” Frontiers in Pharmacology 12 (September). doi:10.3389/fphar.2021.648262.